NVO Novo Nordisk A S stock chart & analysis
Conviction 76HealthcareScan · Fri, Nov 6, 2026Novo Nordisk A S (NVO) closed at $40.31 (+0.02%) on Nov 6, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 53, RS Rating 22, -37.2% from its 52-week high, -20.8% year to date. Sector: Healthcare · Drug Manufacturers - General.
NVO technical analysis
Trend
NVO is in a downtrend: price is below the 50-day, which is below the 200-day moving average. It closed 0.7% below the 50-day ($40.58) and 7.8% below the 200-day ($43.70). ADX(14) at 18 points to a weak trend — more range than direction. It meets 1 of 8 trend-template criteria.
Momentum
RSI(14) is 53, in the bullish half of its range. The MACD histogram is positive. Its RS Rating of 22 puts its weighted 12-month performance ahead of about 22% of the US market.
Volume and volatility
Volume on the latest session ran 0.7× its 20-day average. It trades about $439.6M a day on average. ATR(14) is $1.05, 2.6% of price — its typical daily range. Chaikin Money Flow (-0.14) shows distribution.
Key levels
The chart pattern's support is $37.37 and its resistance $43.39. The 52-week range is $35.12 to $64.16; price is 37.2% below the high and 14.8% above the low. The VWAP anchored at the 52-week high is $43.36, above price.
Performance
NVO returned +0.8% (1 week), +5.5% (1 month), -15.6% (3 months), -12.5% (6 months), -16.8% (1 year), -20.8% (year to date).
About Novo Nordisk A S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Drug Manufacturers - General · Listed 1981 · 69,500 employees
Recent news
- Novo Nordisk: 3 Key Takeaways for Long-Term InvestorsMotley Fool · Wed, Nov 4, 2026
- Novo Nordisk Stock Jumped After Earnings — But Its CEO Won't Give 2027 Guidance. Here's What Investors Should KnowMotley Fool · Wed, Nov 4, 2026
- Novo Surges 5% After Walloping Expectations On The Back Of Its GLP-1 DrugsYahoo Finance · Wed, Nov 4, 2026
- Will Raised Outlook Change Novo Nordisk Stock NarrativeYahoo Finance · Wed, Nov 4, 2026
- Novo hires new CFO as Wegovy pill hits more marketsCfodive · Wed, Nov 4, 2026
- Novo Nordisk AS (NVO) (Q3 2026) Earnings Call Highlights: Obesity Sales Surge 22% as Wegovy ...Yahoo Finance · Wed, Nov 4, 2026
- Novo Nordisk (NVO) Q3 2026 Earnings Call TranscriptMotley Fool · Wed, Nov 4, 2026
- Novo Nordisk Stocks Rise 5.65% While Higher Guidance Meets Diverging Profit MeasuresYahoo Finance · Wed, Nov 4, 2026
- Novo Nordisk CEO says CVS breakup has no material impact on the weight-loss drug giantYahoo Finance · Wed, Nov 4, 2026
- Novo Nordisk Stock Jumps 6% as Wegovy Hits a Stunning 80% Milestone247Wallst · Wed, Nov 4, 2026
Congress activity
Disclosed STOCK Act trades in NVO · 10 recent
| Member | Side | Amount | Traded | Filed | PTR |
|---|---|---|---|---|---|
 Kevin Hern house · R · OK · traded 2026-08-31 | Sell | $1K–$15K | 2026-08-31 | 2026-09-25 | |
Kevin Hern house · R · OK · traded 2026-09-10 | Sell | $1K–$15K | 2026-09-10 | 2026-09-25 | |
 Scott Scott Franklin house · R · FL · traded 2026-08-26 | Buy | $1K–$15K | 2026-08-26 | 2026-09-17 | |
 Alan Armstrong senate · R · OK · traded 2026-03-30 | Buy | $15K–$50K | 2026-03-30 | 2026-07-21 | |
 Lisa McClain house · MI · traded 2025-10-30 | Sell | $1K–$15K | 2025-10-30 | 2025-11-01 | |
Lisa McClain house · MI · traded 2025-10-31 | Sell | $1K–$15K | 2025-10-31 | 2025-11-01 | |
Lisa McClain house · R · MI · traded 2025-09-11 | Buy | $1K–$15K | 2025-09-11 | 2025-10-22 | |
 Marjorie Taylor Greene house · GA · traded 2025-10-15 | Buy | $1K–$15K | 2025-10-15 | 2025-10-20 | |
Lisa McClain house · R · MI · traded 2025-08-04 | Sell | $1K–$15K | 2025-08-04 | 2025-09-12 | |
 Valerie Hoyle house · D · OR · traded 2024-10-29 | Buy | $1K–$15K | 2024-10-29 | 2025-09-12 |
SEC filings
EDGAR filings in NVO · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.